Bioinformatics for single-cell genome sequence analyses and High-throughput mRNA sequencing
From 01-10-2013 to 28-02-2014
Description
SymBioSys is a consortium of computational scientists and molecular biologists at the KU Leuven focusing on how individual genomic variation leads to disease through cascading effects across biological networks. The goal of the project is to develop innovative bioinformatics and computational biology strategies aimed at two key challenges. First, it addresses the technological challenge of efficiently leveraging the flood of data from next−generation sequencing (NGS) towards mapping genomic and transcriptomic variation in human and mouse. Second, it tackles the scientific challenge of understanding how (human) genetic variation originates and how it leads to differences in (clinical) phenotypes.
Two ongoing projects will benefit from the accessibility to Tier1.
The first project refers to the study of DNA mutation rates and mutator phenotypes at per cell-cycle level and to the profiling of the intra-tumor genetic heterogeneity at single-cell level. The goal of the second project is to study the 3’UTR length of RNA transcripts in mature spermatozoa, oocytes and early embryonic cells, hypothesized to be important in the post-transcriptional regulation of gene expression in early embryogenesisTeam
- Yves Moreau, Co-promoter
- Thierry Voet, Promoter (External)
- Parveen Kumar, Team member (External)
- LIgia Mateiu, Team member (External)
Financing
Funding: OTHER - Other Funding Agencies
Program/Grant Type: VSC - Vlaams Supercomputing Centrum
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.